

# ASX Announcement

Proteome Systems Limited ACN 080 277 998

Company Announcements Office  
Australian Stock Exchange

## *Proteome Systems Appoints Two New Directors*

**19 June 2007 Sydney, Australia:** Proteome Systems Limited (ASX:PXL) today announced that it has appointed Mr Roger Amos as an independent director, effective from 18 June 2007. PXL also confirmed the appointment of former CEO, Mr Stephen Porges, as a non-executive director effective from 18 June 2007 and announced the imminent retirement from the Board of Dr Arthur Emmett.

### **Mr Roger Amos**

Proteome Systems' Chairman, Graham Bradley said: "Mr Amos brings with him a wealth of financial experience and commercial insight. His contribution will be particularly valuable as Proteome Systems increases its corporate activities and progresses the commercialisation of its programme portfolio".

Mr Amos had a long and distinguished career with international accounting firm KPMG, retiring in June 2006 after 25 years as a partner in the Assurance and Risk Advisory Services division. In addition to his portfolio of clients, focused on the Information, Communications and Entertainment Industry, Roger held various roles in the KPMG Global ICE industry groups, including Global Chairman of the Communications Industry Group.

Roger is also an independent director of realestate.com.au Limited and Espreon Limited and has a non-executive role as Chairman, Asia Pacific for Management Consulting Group PLC. His prior roles include Deputy Chairman and Audit Committee Chairman of the Film Finance Corporation Australia Limited, Director of Australian Quality Council, Chairman of the Documentary Foundation and President of the State Chamber of Commerce NSW. Mr Amos added: "Over recent months Proteome Systems has made progress in advancing its diagnostic programmes and in realizing the value of its therapeutic portfolio and it is a very exciting time to be joining the board. I look forward to working with the directors and management to develop strategies for the commercialization of the current programme portfolio, and building a robust company with a broad product pipeline and sustainable revenue streams".

### **Mr Stephen Porges**

Mr Bradley continued: "I would like to reaffirm the Board's pleasure that Stephen will retain his association with PXL, providing support to his fellow directors through his knowledge of the Company's business activities and strategies and his extensive experience in capital markets".

Mr Porges was CEO of PXL for 2 years from April 2005, and has recently been appointed CEO of Newcastle Permanent. Stephen has over 20 years' experience in international and investment banking working in all significant global capital markets, and also has considerable experience in developing strategies to reposition and grow companies. Stephen is a director of listed digital services company Hyro Limited, having been Chairman between May 2002 and April 2007, and is a director of corporate advisory business Cabonne Partners.

**Dr Arthur Emmett**

Dr Emmett, who has served on the Board of Proteome Systems since April 2005, is proposing to retire from his role as a director with effect from the conclusion of the next Board meeting, which is set down for 28 June 2007.

Announcing Dr Emmett's imminent retirement, Mr Bradley stated: "We are enormously appreciative of the contribution that Arthur Emmett has made during his term as a director. Arthur's considerable industry experience has been of great assistance in helping to steer the company successfully onto a new course so as to focus its energies and resources on developing commercialisation opportunities in its diagnostics and therapeutics businesses".

**About Proteome Systems**

Proteome Systems Limited [ASX:PXL] is an Australian based biotechnology company that has extensive expertise in discovering biomarkers of disease and identifying their utility as novel diagnostics and therapeutics. The Company has developed proprietary technology platforms and software for biomarker discovery and diagnostic test development. Its strategy is to build multiple revenue streams from multiple products through partners best suited to bringing its products to market. Proteome Systems' product focus is on areas where there are large global markets and an unmet need for diagnostics, such as tuberculosis.

The Company has developed a rapid and quantitative point of care diagnostic test format known as DiagnostIQ. This has been licensed to Bayer CropSciences for manufacture and sales of a WheatRite® test and for the development of other agricultural crop applications. DiagnostIQ is available to 3<sup>rd</sup> parties for development of other diagnostic tests through specialist US partner, Diagnostic Consulting Network. Proteome Systems also has a portfolio of small molecule drug compounds that have application to the treatment of a range of diseases, in particular for dermatological and neurological indications. The first product from the Company's therapeutic portfolio protects against UV-related skin damage and is commercially available in Estée Lauder's DayWear Plus range.

Additional information about Proteome Systems can be found at [www.proteomesystems.com](http://www.proteomesystems.com)

Contact: Jenny Harry  
Chief Executive Officer  
& Managing Director  
Proteome Systems Limited  
+61 2 8877 8947